Dr. Lal PathLabs Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024
May 10, 2024 at 04:11 am EDT
Share
Dr. Lal PathLabs Limited reported earnings results for the fourth quarter and full year ended March 31, 2024. For the fourth quarter, the company reported sales was INR 5,454 million compared to INR 4,910 million a year ago. Revenue was INR 5,638 million compared to INR 5,052 million a year ago. Net income was INR 845 million compared to INR 567 million a year ago. Basic earnings per share from continuing operations was INR 10.13 compared to INR 6.84 a year ago. Diluted earnings per share from continuing operations was INR 10.12 compared to INR 6.82 a year ago.
For the full year, sales was INR 22,266 million compared to INR 20,169 million a year ago. Revenue was INR 22,958 million compared to INR 20,586 million a year ago. Net income was INR 3,577 million compared to INR 2,389 million a year ago. Basic earnings per share from continuing operations was INR 43.05 compared to INR 28.82 a year ago. Diluted earnings per share from continuing operations was INR 42.98 compared to INR 28.74 a year ago.
Dr. Lal PathLabs Limited is an India-based company that is engaged in providing diagnostic and related healthcare tests and services. The Company is engaged in the business of running laboratories for carrying out pathological investigations of various branches of biochemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. It offers a range of tests by condition, which includes allergy, diabetes, health checkups, viral infections, fever, heart diseases, hypertension, cancer, abortions, anemia, arthritis, breast cancer, diphtheria, disorder of the liver, disorders of bone, drugs of abuse, infertility, lymphoma, tuberculosis, ovarian cancer, osteoporosis, multiple sclerosis, muscular disorder, and viral infections. The Companyâs subsidiaries include Paliwal Diagnostics Private Limited, Paliwal Medicare Private Limited, and Dr. Lal PathLabs Nepal Private Limited.